高盛:維持信義光能(0968.HK)目標價25港元 評級“買入”
高盛發表研究報吿指,信義光能(0968.HK)去年收入123億港元,按年上升35.4%,純利45.6億港元,按年上升89%,高於該行預期5%,維持集團目標價25港元及“買入”評級。
高盛表示,集團去年太陽能玻璃的銷售收入99.9億港元,按年增48%,而由於產能擴張,太陽能玻璃銷量按年增長19.6%。集團管理層預料,今年上半年原材料成本將較去年穩定。集團亦有急速擴張的計劃,料太陽能玻璃的均價將因額外的供應量增加而下降。
該行考慮到集團去年業績及由於整個行業的產能增加而導致的潛在價格下降,將2021-2025財年的盈利預測下調最多8%。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.